Please login to the form below

Not currently logged in


This page shows the latest Edurant news and features for those working in and with pharma, biotech and healthcare.

GSK two-drug trial in untreated HIV raises Gilead rivalry

GSK two-drug trial in untreated HIV raises Gilead rivalry

Along with dolutegravir/lamivudine for treatment-naïve patients, it has also been granted regulatory approval for Juluca, a combination of dolutegravir and Johnson &Johnson’s non-nucleoside RTI Edurant (rilpivirine) for

Latest news

More from news
Approximately 2 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...